| http://dbpedia.org/ontology/abstract
|
NL-201 was an immunotherapy drug candidate … NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients. It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington. In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.uld discontinue the development of NL-201.
|
| http://dbpedia.org/ontology/wikiPageID
|
68019800
|
| http://dbpedia.org/ontology/wikiPageLength
|
3861
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1122019590
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Distributed_computing +
, http://dbpedia.org/resource/University_of_Washington +
, http://dbpedia.org/resource/Nature_%28journal%29 +
, http://dbpedia.org/resource/Rosetta@home +
, http://dbpedia.org/resource/Category:Immunotherapy +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Immunotherapy +
, http://dbpedia.org/resource/Pembrolizumab +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
, http://dbpedia.org/resource/Category:Immunotherapy +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/NL-201?oldid=1122019590&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/NL-201 +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q107439451 +
, https://global.dbpedia.org/id/Fx6HC +
, http://dbpedia.org/resource/NL-201 +
|
| rdfs:comment |
NL-201 was an immunotherapy drug candidate … NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients. It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington. In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.uld discontinue the development of NL-201.
|
| rdfs:label |
NL-201
|
